Delivery Order SPE2DB24D9246-SPE2DB25FGUSL

Award Date 3/6/25
Potential Completion Date 3/27/25
Potential Value $5.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $16,020.32 and covers the delivery of NEXPLANON 68 MG IMPLANTS through January 22, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $2,777.24, is for the delivery of NEXPLANON 68 MG IMPLANTS to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a specialized pharmaceutical product, with a ceiling value of $3,573.45 and a period of performance through December 30, 2024. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $5,554.48 contract is for the delivery of NEXPLANON 68 MG IMPLANTS to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which covers a broad range of pharmaceutical...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Nexplanon 68 mg implants, with a ceiling value of $7,146.90 and a period of performance through February 20, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
This is a firm fixed-price delivery order valued at $14,759.04 awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of NEXPLANON 68 MG IMPLANTS, a specialized pharmaceutical product. The contract is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the procurement of NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $4,288.14 and a period of performance through March 7, 2024. This delivery order contract is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999, which enables the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,943.10 firm fixed-price contract is for the delivery of NEXPLANON 68 MG IMPLANTS and is set to expire on February 4, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the issuance of delivery orders for a...
This is a firm fixed-price delivery order for $20,829.30 awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of NEXPLANON 68 MG IMPLANTS, a specialized pharmaceutical product, with a period of performance ending on March 20, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,331.72 order is for the supply of NEXPLANON 68 MG IMPLANTS, a prescription contraceptive device, with a period of performance through March 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders...
  • SPE2DB24D9246
    Indefinite Delivery Contract
  • SPE2DB24D9246-SPE2DB25FGUSL
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the supply of NEXPLANON 68 MG IMPLANTS, a specialized pharmaceutical product, with a ceiling value of $5,554.48 and a period of performance through March 27, 2025.

DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a wide range of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers. The company holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items.

This specific delivery order is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.

Generated 6/5/25, 9:47 AM